Pharmaceutical Investing Novartis Advanced Accelerator Applications Receives FDA Approval for Lutathera
Pharmaceutical Investing Novartis completes tender offer for Advanced Accelerator Applications S.A. and commencement of subsequent offering period
Advanced Accelerator Applications Announces Pricing of $150 Million Public Offering of American Depositary Shares
ITEL signs agreement with Advanced Accelerator Applications to commercialize F-18 radiopharmaceuticals in Southern Italy
Juggernaut Announces Strategic Investment by Crescat Capital Funds for 28.95% Ownership - Dr. Quinton Hennigh Technical Advisor
